A large fraction of genetic risk factors for Alzheimer's Disease (AD) is still not identified,
limiting the understanding of AD pathology and study of therapeutic targets. We conducted a …

Background Alzheimer's disease (AD) is an incurable neurodegenerative disease currently
affecting 1.75% of the US population, with projected growth to 3.46% by 2050. Identifying …

Genome-wide association studies (GWAS) have gained considerable momentum over the
last couple of years for the identification of novel complex disease genes. In the field of …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder with considerable
evidence suggesting an initiation of disease in the entorhinal cortex and hippocampus and …

The genetics of Alzheimer's disease (AD) is heterogeneous and remains only ill-defined. We
have recently created a freely available and continuously updated online database …

Background Genome-wide association studies have identified more than 30 Alzheimer's
disease (AD) risk genes, although the detailed mechanism through which all these genes …

Previous genome-wide association studies (GWAS), conducted by our group and others,
have identified loci that harbor risk variants for neurodegenerative diseases, including …

The classic pathologic hallmarks of Alzheimer's disease (AD) are amyloid plaques and
neurofibrillary tangles (AD neuropathologic changes, or ADNC). However, brains from …

Several common psychiatric and neurodegenerative diseases share epidemiologic risk;
however, whether they share pathophysiology is unclear and is the focus of our …

Objective Alzheimer's disease (AD) is a neurodegenerative disorder for which more than 20
genetic loci have been implicated to date. However, studies demonstrate not all genetic …